Back to Search
JAMES GULLEY, MD PHD FACP
MD PHD FACP
Hematology & Oncology Physician
NPI: 1720038771Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
D0056966(MD)
Research & Publications (20)
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
PMID 18710748·J Urol·2008
3-trial
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
PMID 18483372·Clin Cancer Res·2008
5-case
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
PMID 17956715·Clin Genitourin Cancer·2007
5-case
Future directions in tumor immunotherapy: CTLA4 blockade.
PMID 17327854·Nat Clin Pract Oncol·2007
7-preclinical
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
PMID 17573164·Vaccine·2007
6-review
Clodronate in the prevention and treatment of skeletal metastasis.
PMID 15877520·Expert Rev Anticancer Ther·2005
6-review
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
PMID 15867235·Clin Cancer Res·2005
3-trial
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
PMID 15821487·J Urol·2005
3-trial
Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.
PMID 14747053·Urology·2003
6-review
Treatment options for androgen-independent prostate cancer.
PMID 16227960·Clin Adv Hematol Oncol·2003
6-review
Novel clinical trials in androgen-independent prostate cancer.
PMID 15046713·Clin Prostate Cancer·2002
6-review
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
PMID 12242725·Prostate·2002
3-trial
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
PMID 19495750·Cancer Immunol Immunother·2010
8-other
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
PMID 19167733·J Urol·2009
2-rct
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
PMID 19548854·Expert Opin Investig Drugs·2009
6-review
Combining radiation and immunotherapy for synergistic antitumor therapy.
PMID 19169958·Curr Opin Mol Ther·2009
6-review
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
PMID 19235596·Cancer Invest·2009
3-trial
Promising novel immunotherapies and combinations for prostate cancer.
PMID 19284377·Future Oncol·2009
6-review
Cancer vaccines: current directions and perspectives in prostate cancer.
PMID 19169957·Curr Opin Mol Ther·2009
6-review
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
PMID 19451403·J Clin Pharmacol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10 CENTER DR., 8B08, MSC 1750
BETHESDA, MD 20892 - Phone
- (301) 435-2956
Quick Facts
- NPI
- 1720038771
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile